HTR1B and migraine disorder: The first specific antimigraine drugs developed were the ergot alkaloids, which demonstrate non-specific agonism for 5-HT1 receptors (63) with a central effect through activation of 5-HT1B, 5-HT1D, and 5-HT1F receptors on trigeminal nerve terminals, inhibiting the release of vasoactive peptides preventing vasodilatation in migraine (64).